NADMED has launched two kits, Q-NADMED and Q-NAD. Q-NADMED is the first kit available for whole blood NAD+ and NADH analysis; the first CE-marked kit for NAD analysis; and the only EU IVDD-compliant kit for NAD+ and NADH analysis from blood.
NADMED technology is based on proprietary extraction and the individual measurement of NAD metabolites, allowing excellent accuracy comparable to mass spectrometry. Q-NAD kits use the same approach for the four NAD metabolites: NAD+, NADH, NADP and NADPH.
The lack of a quick and reliable method has been a challenge for measuring NAD+, a molecule that is a major metabolism regulator. NADMED technology offers a unique, scalable and cost-effective solution to extract all NAD metabolites and eliminate inaccuracies in the individual measuring process. This technology also saves time. While mass spectrometer analysis takes days, NADMED analysis is ready in four hours. Furthermore, NADMED brings the analysis accessible to laboratories without access to mass spectrometry, at only a fraction of a mass spectrometer’s total costs.
Recent studies at Helsinki University show that patients with mitochondrial muscle disease had NAD deficiency detectable in blood, and benefited remarkably from NAD booster treatment. "NAD analysis from blood is a very important new tool to detect NAD deficiency, find correct dosing of NAD boosters, and follow up the treatment," said Anu Suomalainen Wartiovaara, Academy Professor of Clinical Molecular Medicine at Helsinki University, and a NADMED co-founder.